Although few data are available, the analysis of ctDNA could provide several advantages in clinical practice of PDAC [40] and it should be useful also for the evaluation of BRCA1/2 gene mutations, particularly when tumor tissue is not available or adequate. Here, BRCA1 is linked to neoplasm.